HFNC Effect on BCSS in Patients With COPD
| Status: | Recruiting |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 35 - 80 |
| Updated: | 5/6/2018 |
| Start Date: | February 2016 |
| End Date: | December 2019 |
| Contact: | Karen Allen, MD |
| Email: | karen-allen@ouhsc.edu |
| Phone: | 405-271-6173 |
Effect of High-Flow Nasal Cannula (HFNC) on the Breathlessness, Cough, and Sputum Scale (BCSS), in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to look for a correlation between the use of HFNC in
the outpatient setting in patients with previous COPD exacerbation and the change in their
BCSS score. The hypothesis is that home use of HFNC will lead to a reduction in BCSS score by
1.3.
the outpatient setting in patients with previous COPD exacerbation and the change in their
BCSS score. The hypothesis is that home use of HFNC will lead to a reduction in BCSS score by
1.3.
This is a prospective pilot study. Targeted population include patients with COPD, non-oxygen
dependent, with a baseline normal bicarbonate on previous lab (within 6 months of
enrollment). Patients will be randomly selected to be part of the study sample. Recruitment
will occur in both inpatient and outpatient settings. An email briefly explaining the
objectives of the study will be sent to Internal Medicine residents and Pulmonary Critical
Care fellows to help in patients' recruitment. Patients will be enrolled in the study only
after being seen by Dr. Abdo or Dr. Allen. The study is expected to finish by the end of
January 2017 or twelve months post IRB approval. Patients will be recruited and enrolled over
six months, and the collected data will be analyzed six months after the last patient was
included in the study. The study will target a study sample of 30 as detailed in the
statistical analysis section, where patients will be their own control (3 months without HFNC
followed by 3 months with HFNC).
dependent, with a baseline normal bicarbonate on previous lab (within 6 months of
enrollment). Patients will be randomly selected to be part of the study sample. Recruitment
will occur in both inpatient and outpatient settings. An email briefly explaining the
objectives of the study will be sent to Internal Medicine residents and Pulmonary Critical
Care fellows to help in patients' recruitment. Patients will be enrolled in the study only
after being seen by Dr. Abdo or Dr. Allen. The study is expected to finish by the end of
January 2017 or twelve months post IRB approval. Patients will be recruited and enrolled over
six months, and the collected data will be analyzed six months after the last patient was
included in the study. The study will target a study sample of 30 as detailed in the
statistical analysis section, where patients will be their own control (3 months without HFNC
followed by 3 months with HFNC).
Inclusion Criteria:
One previous COPD exacerbation in last year.
Exclusion Criteria:
Can not be oxygen dependant PaCO2 < 60
We found this trial at
1
site
1100 N. Lindsay
Oklahoma City, Oklahoma 73104
Oklahoma City, Oklahoma 73104
(405) 271-4000
Phone: 405-271-1673
University of Oklahoma The OU Health Sciences Center is composed of seven health-related colleges located...
Click here to add this to my saved trials
